Laurus Labs — the down-cycle ends, the capex never did

The State of Play

Laurus Labs spent FY26 completing one of Indian pharma’s cleaner cyclical recoveries. Two years after net profit cratered to ₹162 crore (FY24) from the COVID-era ARV windfall’s ₹984 crore peak, FY26 closed — per the financial tables; the Q4 call transcript wasn’t retrievable — at ₹6,813 crore of revenue, a 26% operating margin, and ₹890 crore of net profit, with the March 2026 quarter the best in the company’s history. The engine of the recovery is the CDMO business (contract development and manufacturing for global innovators), now over 30% of revenue and aspiring to 50%; the foundation under it is an antiretroviral franchise that serves roughly 40% of the developing world’s HIV patients and is guided, deliberately, to go nowhere. Meanwhile the capex program has only grown: ~₹1,000 crore a year, a ₹5,000 crore five-year Vizag plan, and a new $600 million, 532-acre complex on top.

The Company

Founded in 2005 by Dr. Satyanarayana Chava — still CEO, with the next generation (Krishna Chaitanya and Soumya Chava) now running CDMO and Generics — Laurus is a research-driven API and CDMO house: 6,500+ employees including ~1,050 scientists, 11+ facilities approved by the USFDA, EMA, WHO and peers, 92 DMFs filed. Two reporting engines: Generics (the world’s leading third-party supplier of antiretroviral APIs, plus oncology and other APIs, and a growing formulations business) and CDMO — small-molecule synthesis for big pharma (over 110 active projects, majority Phase 2/3, three commercial NCEs supplied in 18 months), plus Laurus Bio (precision fermentation, its 200,000-litre Bangalore capacity sold out) and a fan of early bets: ADCs (payloads, linkers, now conjugation via a $2 million Aarvik stake), gene-therapy vectors, peptides, CAR-T through associate ImmunoACT, even OLED materials.

Promoters hold a stable ~27.5%; FIIs ~26%. The cyclicality is written all over the ten-year table: 15–21% operating margins pre-COVID, 32% in FY21, 15% in the FY24 trough, 26% in FY26. Net debt peaked at ₹2,764 crore and has been worked down to ~₹2,100 crore (1.2x EBITDA) even while spending ₹1,000 crore a year, because operating cash conversion jumped to 113% of EBITDA in 9M FY26 — against a 63% ten-year average — helped by customer advances. The stock trades at ~88x earnings; when an analyst told management on the April call that the multiple made him “uncomfortable,” Chava’s answer was complete: “How can we comment on PE.”

The Story So Far

Q4 FY25 (call: April 24, 2025) — recovery confirmed, nothing quantified

FY25 closed at ₹5,554 crore (+10%) with EBITDA margin up four points to 20.1% and PAT up 122% to ₹358 crore (₹258 crore per the call’s 12-month framing). The mix shift that defines the thesis was laid out: ARV down from 67% of revenue to 45% in five years, CDMO up from 13% to 28% — with CDMO small-molecule growing 49% in FY25. The forward stance set the house style: “FY ‘26 growth looks good, and then we will achieve significant growth in revenues and profits. That much we can tell you” — and not a single number more, except two that mattered: ARV guided flat at ₹2,400–2,600 crore (“not just FY26, even next 2–3 years”), and capex guided to ~₹1,000 crore. The dated commitments: Vizag fermentation ground-breaking by June 2025, the Krka JV ground-breaking by June 2025, ImmunoACT’s 2,500-treatment CAR-T facility ready by September 2025. On US funding risk to ARVs (the USAID question), the answer was precise: ~₹250 crore of formulation exposure, “it is not that we are going to lose ₹250 crores sales.”

Q1 FY26 (call: July 25, 2025) — the margin ratchet begins

June-quarter revenue rose 31% to ₹1,570 crore with EBITDA margin at ~25% — up 10.5 percentage points YoY — and gross margin near 59.5%. The gross-margin guidance, which had been “around 52%” then “around 55%,” moved to “between 55% to 60%.” CDMO crossed 30% of revenue and got its destination: “we expect it has the potential to touch 50%. That’s our guesstimate” — explicitly no timeline. The capex program got its first big expansion: ₹5,000 crore over 4–5 years in Vizag, funded internally, with net debt capped at 50% of revenue. The Bio division’s fine print mattered: Phase 1 fermentation (400+ KL) online only by end-CY2026, so no significant Bio ramp for five-six quarters — a promise of stagnation that held exactly.

Q2 FY26 (call: October 23, 2025) — $600 million more, and 25% in two years

Revenue ₹1,653 crore (+35%), EBITDA margin 26%, net debt/EBITDA down to 1.3x. CDMO’s first half ran +88% YoY; Generics +28% on ARV volumes; even Bio recovered to ₹47 crore. The announcement: 532 acres from the Andhra Pradesh government and a $600 million, 8-year commitment — on top of, not instead of, the ₹5,000 crore plan, taking the combined long-term envelope to “maybe ₹8,000 crores… Around.” Gross margin guidance ratcheted again — “Now we are saying it is closer to 60%” — and a return-ratio marker was set: “We need at least two more years where our return ratios will improve closer to 25%.” The sharpest exchange was Chandramouli of Techfun comparing Laurus’s CDMO capex returns unfavourably to Divi’s; Chava’s answer — new modalities front-load capex, the late-stage-to-commercial gap runs 18–24 months, “return on capital will normalize in a few more years” — is the bull-bear divide in one paragraph.

Q3 FY26 (call: January 23, 2026) — a soft CDMO quarter, met with a raised ARV guide

Revenue ₹1,778 crore (+26%) at a 27% EBITDA margin and 60.9% gross margin; nine-month PAT of ₹610 crore was up 388%. The wrinkle: CDMO small-molecule printed ₹408 crore, down 13% sequentially — “phasing of deliveries… very long and complex synthetic processes” — drawing pointed questions about a plateau. Management’s response was characteristic: look annually, Q4 FY26 CDMO will beat Q4 FY25’s ₹461 crore, and “majority of FY’27 revenues in our CDMO division will be commercial supplies.” Meanwhile the ARV business, guided flat forever, was running ahead of plan — guidance moved up to ₹2,600 ±200 crore, the result, per the CFO, of six quarters of process and raw-material work rather than pricing. Cash conversion (113% of EBITDA) drew the most genuinely new praise. The modality clocks were restated: peptide facility qualification during CY2026, ADC GMP facility live in ~12 months ($25 million, no revenue for ~24), Krka Phase 1 mid-2027 with revenue from Q1 FY27, the greenfield’s land handover in Q4 FY26.

Q4 FY26 — the scoreboard (from the financials)

The March quarter, per the screener tables: sales ₹1,812 crore, operating margin 28%, net profit ₹282 crore — all records. Full-year FY26: revenue ₹6,813 crore (+23%), operating profit ₹1,778 crore (+69%), PAT ₹890 crore (+149%), ROCE restored to ~18% from FY24’s 7%, free cash flow positive at ₹560 crore despite the spend.

The ledger: said vs. delivered

Kept: “significant growth in revenues and profits” — by any reading; the margin ratchet, where each raise (52% → 55% → 55–60% → ~60% gross; “higher” EBITDA each year) was conservative against the print; ARV inside its guided band all year, then honestly re-guided up; capex ~₹1,000 crore as stated; net debt falling while spending, exactly per the ”±₹250 crore” frame; the Bio stagnation call (it stagnated, as promised, at ₹29–47 crore a quarter); no equity dilution. Delivered on dates, so far as visible: Vizag and Krka ground-breakings, ImmunoACT capacity, the API debottlenecking “completed as promised.” Open, and the real test: the Q4 FY26 CDMO-beats-₹461-crore promise (unverifiable without the Q4 call, though the record quarter suggests it); the two-year path to ~25% return ratios; CDMO’s 50% destination; and whether ₹8,000 crore of capex across fermentation, peptides, ADCs, gene therapy and a greenfield complex — much of it revenue-silent until CY2026–FY28 — earns its keep. The house style: generous with direction and dated project milestones, allergic to quantified revenue guidance (“the numbers only will speak”).

Where Things Stand

Laurus enters FY27 with every engine pointed up on its own telling: CDMO majority-commercial, generics API/FDF set for “some growth in FY27, significant in FY28,” Krka JV revenue starting Q1 FY27, ARV at a raised and “sustainable” ₹2,600 crore run-rate, gross margins guided to hold ~60% through FY27. The capacity wave lands on a schedule worth diarising: peptides qualified during CY2026, Bio’s 400 KL fermentation by end-CY2026, the ADC GMP facility in early CY2027, Krka Phase 1 and the Hyderabad FDF plant mid-2027, the greenfield’s capex starting H2 FY27. The bear case is unchanged from Chandramouli’s January question — heavy, front-loaded capital against returns that are promised but not yet at 25% — and the multiple (~88x) already assumes the answer. The bull case is the last six quarters: every conservative guide beaten, cash conversion transformed, and a CDMO pipeline management claims has never lost business for want of capacity.

The Four Checks

1. Quality and moat. A decent business with a real but narrow edge, not a fortress. The durable piece is regulatory and relationship capital: 11+ facilities approved by the USFDA, EMA and WHO, 92 DMFs, and a position as the world’s leading third-party ARV API supplier — roughly 40% of the developing world’s HIV patients run on its molecules. The CDMO arm adds the classic switching-cost moat of qualified suppliers (110+ active projects, three commercial NCEs in 18 months), but that moat is still under construction and competes against bigger, longer-established rivals — the Divi’s comparison from the October call cut exactly here. The ARV anchor, meanwhile, is a tender-driven, donor-funded market that management itself guides flat forever. The ten-year margin swing — 15% to 32% and back to 15% — says the business cannot yet set its own prices through a cycle.

2. Returns on incremental capital and runway. Modest returns, long runway, trend improving. ROCE ran 8–16% in the pre-COVID years, spiked to 40% in the FY21 ARV windfall, collapsed to 7% in FY24, and has recovered to 18% in FY26; three-year average ROE is just 10.3%. So through a full cycle a rupee reinvested here has earned low-to-mid teens, and the decade of near-zero free cash flow (FCF was negative or negligible in nine of the last twelve years before FY26’s ₹560 crore) shows how much of the surplus the engine consumes — including 317 inventory days and a 263-day cash conversion cycle. The runway is the better half of the story: ₹8,000 crore of planned deployment into CDMO, fermentation, peptides and ADCs, with management marking a path to ~25% return ratios in two years. That marker is a promise, not yet a print.

3. Capital allocation for the stage. Rational, with the verdict pending. For a business that believes its incremental returns are about to clear 20%, the playbook is being run correctly: ~₹1,000 crore a year of internally funded capex, capex sustained straight through the FY24 trough, net debt worked down to ~1.2x EBITDA while spending, a token dividend (7% payout in FY26) during the build phase, no equity dilution, and small, focused bolt-ons (a $2 million ADC stake, the ImmunoACT associate) rather than empire-building. No buyback history is visible in the data, but at these prices none is called for. The honest quibble is that the same conviction-capex through the down-cycle produced the 7% ROCE of FY24 — the allocation only grades out well if the 25% target lands.

4. Price. Demanding, bordering on priced-for-perfection. As of the June 2026 snapshot the stock trades at ₹1,420 — near its 52-week high of ₹1,457, against a low of ₹641 — at 86x earnings and 14.4x book, for a business whose FY26 ROCE is 18% and whose five-year sales growth is 7.2%. The multiple already capitalises the CDMO-at-50%, returns-at-25% future that management has dated but not delivered; even the record FY26 (PAT ₹890 crore, +149%) only restores earnings to roughly the FY21 peak. A buyer at this price is paying up front for the next capex wave to earn its keep on schedule, with the cycle’s history as the counter-argument.

Sources

• Concall transcripts (4): Q4 FY25 (Apr 24, 2025), Q1 FY26 (Jul 25, 2025), Q2 FY26 (Oct 23, 2025), Q3 FY26 (Jan 23, 2026) — BSE filings, converted to markdown. The Q4 FY26 (May 2026) transcript was not retrievable (the screener link served a web page, not a PDF), and the Sep 2025 entry was a presentation only; Q4 FY26 outcomes are from the screener financial tables.
• Annual reports (3): FY23, FY24, FY25 sections — thin extracts; main contribution was the export-led revenue shape and capex pacing (FY23 ₹990 crore → FY25 ₹641 crore).
• Screener.in snapshot: consolidated quarterly and annual tables, ratios, shareholding — fetched 2026-06-05 (logged-out session).
• Research files: vault/Sources/Earnings/Laurus Labs Ltd/ — raw transcripts, AR sections, snapshot, per-document digests (not published).